Table 3.

Impact of AOM on comorbidities and societal value by age and race

Subgroup	15% uptakea	15% uptake, next generationa	30% uptake, next generationa
Reduction in total years lived with comorbidities, compared with status quo, $ (million)
Comorbidity
Cardiovascular diseases	11.0	13.5	17.2
Type 2 diabetes	53.8	76.7	101.6
Depression	5.4	8.4	11.5
Osteoarthritis	13.5	19.3	25.2
Increase in per person societal value, compared with status quo, $ (thousand) b
Age category, y c
25‐34	9.6	15.3	19.8
35‐44	8.5	13.7	18.2
45‐54	6.1	9.8	13.1
55‐64	3.2	5.1	6.9
65‐74	0.5	1.4	1.9
Race
White	4.4	7.2	9.7
Black	7.3	11.7	15.2
Hispanic	7.8	12.6	16.4

^aThe status quo scenario represents current rates of diet and exercise and no AOM use. The 15% uptake scenario represents 15% annual AOM uptake among eligible treatment‐naïve individuals starting in 2019. The 15% uptake, next generation scenario represents 15% annual AOM uptake among eligible treatment‐naïve individuals starting in 2019 and the availability of more efficacious AOM in 2023 onward. The 30% uptake, next generation scenario represents 15% annual AOM uptake among eligible treatment‐naïve individuals starting in 2019 until 2023 and the availability of more efficacious AOM combined with higher uptake (30%) in 2023 onward.

^bIncrease in per person societal value for each category calculated as increase in total societal value accrued to that category, compared with status quo, divided by number of individuals in that category.

^cAge category defined as age category of individuals in cohort at beginning of simulation in 2019; AOM, antiobesity medications.